A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 984 participants.
Also called NCT04460885
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 984 participants
- Sponsor
- Registry
-
NCT04460885 -
2020-000442-34
-
- Other papers using this trial's data
- Continuous glucose monitoring-based metrics and the duration of hypoglycaemia events with once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-naive type 2 diabetes: an exploratory analysis of ONWARDS 1
- Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Croatia, India, Israel, Italy, Japan, Mexico, Poland, Puerto Rico, Russia, Slovakia, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT04460885. Randomized; no masking; primary purpose treatment. Start 2020-11-25 (actual); primary completion 2022-05-29 (actual). Results posted on 2025-06-12.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before
- Acronym
- ONWARDS 1
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Insulin icodec
- Intervention (Drug)
- Insulin glargine
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct04460885- Content hash
a6dc0a0641ea1dbd9e5db2164fefab82d12b2983a6ddb7079d39e82e9c1f698e